Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of WS016 in Healthy Chinese Volunteers
NCT06281470Phase 1Completed
- Sponsor
- Waterstone Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of WS016 in hyperkalemia (10 arms), sponsored by Waterstone Pharmaceuticals. Primary endpoint: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Feb 2023; status: completed.
02
Drugs
WS016
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT06281470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281470.